LCTX vs. LLY
LCTX (Lineage Cell Therapeutics, Inc.) and LLY (Eli Lilly and Company) are both stocks. Both are in the Healthcare sector — LCTX in Biotechnology, LLY in Drug Manufacturers - General. Over the past 10 years, LCTX returned -6.85%/yr vs 32.66%/yr for LLY. At a 0.10 correlation, their price movements are largely independent.
Performance
LCTX vs. LLY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, LCTX achieves a -28.14% return, which is significantly lower than LLY's 0.72% return. Over the past 10 years, LCTX has underperformed LLY with an annualized return of -6.85%, while LLY has yielded a comparatively higher 32.66% annualized return.
LCTX
- 1D
- -0.83%
- 1M
- -15.49%
- YTD
- -28.14%
- 6M
- -28.57%
- 1Y
- 76.99%
- 3Y*
- -3.13%
- 5Y*
- -15.95%
- 10Y*
- -6.85%
LLY
- 1D
- 1.37%
- 1M
- 11.64%
- YTD
- 0.72%
- 6M
- 4.73%
- 1Y
- 44.70%
- 3Y*
- 35.56%
- 5Y*
- 41.13%
- 10Y*
- 32.66%
LCTX vs. LLY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
LCTX Lineage Cell Therapeutics, Inc. | -28.14% | 232.34% | -53.90% | -6.84% | -52.24% | 39.20% | 97.75% | -2.52% | -51.46% | -40.44% |
LLY Eli Lilly and Company | 0.72% | 40.25% | 33.30% | 60.91% | 34.26% | 66.08% | 31.04% | 16.14% | 40.45% | 17.83% |
Correlation
The correlation between LCTX and LLY is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.19 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.15 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.14 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.14 |
Correlation (All Time) Calculated using the full available price history since Mar 9, 1992 | 0.10 |
Fundamentals
LCTX:
$313.41M
LLY:
$966.48B
LCTX:
-$0.27
LLY:
$28.14
LCTX:
19.25
LLY:
13.41
LCTX:
5.95
LLY:
30.98
LCTX:
$14.78M
LLY:
$72.25B
LCTX:
$12.25M
LLY:
$59.75B
LCTX:
-$48.30M
LLY:
$32.97B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LCTX vs. LLY — Risk / Return Rank
LCTX
LLY
LCTX vs. LLY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Lineage Cell Therapeutics, Inc. (LCTX) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| LCTX | LLY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.05 | ||
| Sortino ratioReturn per unit of downside risk | +0.24 | ||
| Omega ratioGain probability vs. loss probability | 1.22 | 1.24 | -0.02 |
| Calmar ratioReturn relative to maximum drawdown | 2.00 | 1.90 | +0.10 |
| Martin ratioReturn relative to average drawdown | 5.00 | 4.73 | +0.27 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| LCTX | LLY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.14 | 1.19 | -0.05 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.22 | 1.26 | -1.49 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.09 | 1.09 | -1.18 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.03 | 0.57 | -0.60 |
Drawdowns
LCTX vs. LLY - Drawdown Comparison
The maximum LCTX drawdown since its inception was -99.31%, which is greater than LLY's maximum drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for LCTX and LLY.
Loading charts...
Drawdown Indicators
| LCTX | LLY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.31% | -68.24% | -31.07% |
Max Drawdown (1Y)Largest decline over 1 year | -38.78% | -23.64% | -15.14% |
Max Drawdown (3Y)Largest decline over 3 years | -74.76% | -34.48% | -40.28% |
Max Drawdown (5Y)Largest decline over 5 years | -86.91% | -34.48% | -52.43% |
Max Drawdown (10Y)Largest decline over 10 years | -88.88% | -34.48% | -54.40% |
Current DrawdownCurrent decline from peak | -93.85% | -4.26% | -89.59% |
Average DrawdownAverage peak-to-trough decline | -78.70% | -19.22% | -59.48% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.46% | 9.49% | +5.97% |
Volatility
LCTX vs. LLY - Volatility Comparison
Lineage Cell Therapeutics, Inc. (LCTX) has a higher volatility of 14.68% compared to Eli Lilly and Company (LLY) at 9.16%. This indicates that LCTX's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| LCTX | LLY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.68% | 9.16% | +5.52% |
Volatility (6M)Calculated over the trailing 6-month period | 39.95% | 26.81% | +13.14% |
Volatility (1Y)Calculated over the trailing 1-year period | 68.11% | 37.88% | +30.23% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 71.51% | 32.79% | +38.72% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 75.25% | 30.14% | +45.11% |
Dividends
LCTX vs. LLY - Dividend Comparison
LCTX has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.60%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
LCTX Lineage Cell Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 8.66% | 0.00% |
LLY Eli Lilly and Company | 0.60% | 0.56% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% |
Financials
LCTX vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between Lineage Cell Therapeutics, Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
LCTX and LLY have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LCTX has higher volatility (14.68%) compared to LLY (9.16%). In terms of maximum drawdown, LCTX dropped -99.31% vs LLY's -68.24%.
LLY currently has the higher Sharpe Ratio (1.19 vs 1.14), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for LCTX and LLY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer